Just as CMS moves ahead with payment reforms designed to reduce the total cost of hospital care, results from a new study show that cancer treatment costs remain significantly lower at community oncology clinics compared with hospitals.
January 2018
Improving outcomes for disadvantaged patients with lung cancer has been a priority for over 5 years at Mary Bird Perkins-Our Lady of the Lake Cancer Center in Baton Rouge, Louisiana.
According to the results of the randomized phase III AXEPT clinical trial, a chemotherapy doublet has proved noninferior to treatment with standard FOLFIRI (folinic acid [leucovorin], fluorouracil [5-FU], and irinotecan) for patients with previously treated metastatic colorectal cancer (mCRC).<sup>1</sup>
The MET oncogene has become a rapidly rising target for the treatment of patients with non–small cell lung cancer (NSCLC), according to Balazs Halmos, MD, MS.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
